Skip to content
Boost Up Blog – Lifestyle
Author:
Vector Sciences & Therapeutics
Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies
July 15, 2026
Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio
July 7, 2026
Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform
June 30, 2026
Gary Payton II Named Chief Athletic Ambassador of Valor
June 22, 2026
Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform
June 12, 2026
Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor
June 8, 2026
Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy
June 2, 2026
/C O R R E C T I O N — Vector Sciences & Therapeutics/
May 22, 2026
Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing
May 21, 2026
Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC
May 11, 2026
←
Previous Page
1
2
3
Next Page
→